Track Trevena, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Trevena, Inc. TRVN · Stock Open Trevena, Inc. in new tab

0.000500 USD
EPS
-1.76
P/B
0.00
Beta
-1.88
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-1.76
Book Value-27.27
Price to Book0.00
% Insiders0.484%
Growth
Revenue Growth0.57%
Estimates
Forward P/E0.00
Forward EPS-19.85

DCF valuation

Model fair value for Trevena, Inc. (TRVN)
Result
Sign in to run the valuation for TRVN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Trevena, Inc. Analysis (TRVN)

United States Health Care Stock

Is Trevena, Inc. a good investment? Trevena, Inc. (TRVN) is currently trading at 0.000500 USD.

Earnings Schedule: Trevena, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -19.85.

Investor FAQ

Does Trevena, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Trevena, Inc.?

Trevena, Inc. is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -1.76.

Company Profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trades
No dividend information available for this instrument.

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion